You are currently viewing our desktop site, do you want to download our app instead?
Moneyweb Android App Moneyweb iOS App Moneyweb Mobile Web App

NEW SENS search and JSE share prices

More about the app

British American Tobacco is flying high

Announces breakthrough in potential vaccine for Covid-19 as full-year results demonstrate its resilience.
The group has made a R2.6bn investment in cannabis, and is transforming tobacco plants into ‘biomanufacturing plants’ for use in pharmaceuticals. Image: Cole Burston, Bloomberg

British American Tobacco plc (BAT) has published its annual report for the year ended December 31, 2020, which indicates not only strong resilience in the face of Covid-19, but also gives notice of an exciting breakthrough in developing a potential vaccine for Covid-19. 

Financial highlights

Revenue per geographic region after adjusting for currency exchange rates

£m 2020 2019
United States 11 473 10 373
Asia-Pacific and Middle East 4 537 5 153
Americas and sub-Saharan Africa 3 772 4 261
Europe and North Africa 5 994 6 090
25 776 25 877
Profit for the year 6 564 5 849
Comprehensive profit after tax, exchange differences and other 3 622 2 126

Revenue growth, somewhat offset by Covid-19 headwinds, was driven by New Categories (products that don’t burn tobacco, but deliver nicotine to the user) and Combustibles.


Intangible assets of £115.3 billion (2019: £118.8 billion) comprise 83.8% (2019: 84.2%) of total assets of £137.7 billion (2019: £141 billion).

Borrowings are £44 billion (2019: £45.4 billion) and finance costs are £1.7 billion (2019: £1.6 billion). Total trade and other payables are again sitting at £10.8 billion (2019: £10.8 billion).

BAT sells to 150 million consumers, including 13.5 million non-combustible product consumers, in over 180 markets and has more than 55 000 employees.

It acknowledges the serious health risks attached to tobacco products and encourages smokers to switch to “scientifically-substantiated reduced-risk alternatives”. BAT is “transforming into a consumer-centric multi-category consumer products business”.

Independent auditor’s report

The auditor, KPMG LLP, confirms that the financial statements give a true and fair view of the group and company’s affairs as at December 2020.

Key audit matters include the risk of material misstatement in the financial figures.

Significant risks are:

  1. The 2017 acquisition of Reynolds American Inc resulted in goodwill of £32.7 billion (2019: £33.8 billion) and trademarks of £68.8 billion (2019: £71 billion). Significant auditor judgement is required in considering any impairment and in evaluating the fair value of these intangible assets.
  2. The group is subjected to a large number of claims, including class actions, with the most significant risk relating to Canada. Provision will be made at such time as an unfavourable outcome is expected.

BAT joins drive to develop a Covid-19 vaccine

BAT’s US biotech subsidiary Kentucky BioProcessing (KBP) is a world leader in “using tobacco plants to express, extract and purify proteins for use as vaccines and other pharmaceuticals”.

This includes transforming tobacco plants into “biomanufacturing plants” that produce proteins which would not otherwise be produced. The extracted protein is purified for pharmaceutical and commercial applications.

The tobacco plant that is used, Nicotiana benthamiana, is not used in the production of more traditional tobacco products. According to BKP it has a number of characteristics that make it ideal for “biomanufacturing recombinant proteins”.

KPB is developing a potential vaccine for Covid-19.

In 2020 it cloned a portion of Covid-19’s genetic sequence and developed a potential antigen.

This was then injected into the tobacco plants to result in a purer form of the antigen on harvesting. When harvested, the plant is crushed to create a green-juice slurry, from which the protein is extracted.

The US Food and Drug Administration (FDA) approved the new drug application in December 2020, and the vaccine candidate, KPB-201, is progressing through the Phase 1 study. This is an officially registered trial, NCT04473690. If successful, KPB-201 will progress to the development programme that will fully assess its safety and efficacy.

KBP claims that: “Using plants to create complex products means the process can be done faster and less expensively compared to traditional methods that involve animals, yeast, bacteria, cold storage requirements and other means.”

According to the Vaccine Tracker website, KPB-201 has since progressed to Phase 2 Clinical Trials.

There are 180 participants in the trial. They will participate in the study for approximately one year from the first dose. The estimated study completion date is March 23, 2022.

Latest developments, post balance sheet

In March 2021 BAT made its first investment in cannabis, with a capital injection of C$221 million (R2.6 billion) to acquire a 19.9% equity interest in Organigram, a Canadian producer of high quality medical and recreational cannabis.

Read: Marijuana is going global at a rapid pace (Mar 15)

BAT and Organigram have entered into a product development collaboration agreement. This will entail establishing a ‘Centre of Excellence’ to focus on developing the next generation of cannabis products.

BAT’s share price has risen 12.32% over the last 12 months, and is now sitting at R570.70 a share.

* Curson owns shares in BAT.

Please consider contributing as little as R20 in appreciation of our quality independent financial journalism.



Sort by:
  • Oldest first
  • Newest first
  • Top voted

You must be signed in to comment.


Into the BAT cave

Not sure where you get 12%, as i see 3.24%. They did poorly, compared to other years
Anyway, BAT got shafted by the Government for no reason.

Data obtained from the Moneyweb data section. Data/click a company/BAT. 12 months = March 2020 – March 2021. Ytd = January 2021 – current date.

Well in light of the absence of any Vaccine Policy in this country…we welcome BATS new vaccine idea with open arms!
Better than nothing…and with the negative hate speech from Boris and Co who continue to label the variant as “The South African variant” we won’t be expecting any tourism to this country any time soon! To say nothing of the fact that South Africans won’t be able to visit any other country in the world either! All those South African children and Grandchildren now living overseas thanks to racist BEE policies here won’t be getting a visit from family for a long time. So much for the world becoming a smaller place. Globalization is dead dead dead! And the First World countries killed it!

End of comments.





Follow us:

Search Articles:
Click a Company: